Skip to main content
Premium Trial:

Request an Annual Quote

DeCode Announces SNP Discovery, Reiterates Revenue Projections

NEW YORK, July 1 - DeCode Genetics announced progress in several areas of its population genetics and target discovery research today, while reiterating that it will meet its revenue and cash-burn goals for the year.


The Reykjavik, Iceland, company announced in connection with an investor meeting that it had identified a set of SNPs on chromosome 5 that increases the risk of stroke by two-fold, and another one that doubles the risk of type 2 diabetes.


The company also said it had confirmed an earlier finding of a genetic mutation that increased risk for osteoporosis in studies outside Iceland. DeCode said it would receive milestone payments from its partner, Roche, on these findings.


DeCode additionally said that small-molecule lead discovery programs for schizophrenia, atherosclerosis, and peripheral arterial occlusive disease are progressing, and that it had identified a novel kinase target for asthma.


The company said it expects to receive $45 million in revenue for the year under its current contracts, and to burn $20 million in cash. The company had $93.2 million in cash and cash equivalents at the end of 2002.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.